-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gosherin is a gonagogic hormone-releasing hormone astigid.
LY01005 is used in the treatment of breast cancer, prostate cancer and endometriosis and other conditions.
the drug is given at a monthly frequency through intramuscular injections, resulting in a smooth release of the drug during the administration cycle.
Currently, Greenlee Pharmaceuticals has obtained a patent in China for the Goscherelin Microcosm Drug Composition and filed a Patent Cooperation Agreement (PCT) application for the Gosherlin Microball Pharmaceutical Composition in 2014, which entered the United States, Europe, Japan, and several other countries and regions in 2015, including the United States, Europe and Japan.
prostate and breast cancer are among the most common cancers that threaten the health of both men and women, and the incidence rate is among the highest in the world.
like most other countries, the incidence of these two diseases in China is on the rise.
from the patient's drug demand, according to IQVIA statistics: in 2019, China's market value of progesterone-releasing hormone agonist products reached about 5.828 billion yuan, an increase of 17.71 percent year-on-year.
note: There are deletions in the original text